D-0383-2021 Class II Ongoing

Recalled by Hyobin LLC — Ridgewood, NJ

FDA drug recall D-0383-2021 was initiated by Hyobin LLC on Apr 6, 2021 and is designated Class II. Reason for recall: Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil. The recall status is ongoing. Affected quantity: 300 cards.

Recall details

Product Type
Drugs
Report Date
May 26, 2021
Initiation Date
Apr 6, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
300 cards

Product description

Triple SupremeZen Plus 3500, packaged in cardboard blisters containing one capsule per card, Distributed by Yolo Studio, Cliffside Park, NJ

Reason for recall

Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil.

Distribution pattern

USA Nationwide

Code information

all lots

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0383-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0383-2021. Report a data issue: hello@regdatalab.com.